ACXP - Acurx signals ongoing cost controls and new trial funding avenues while advancing ibezapolstat clinical program
2025-08-12 10:14:26 ET
More on Acurx Pharmaceuticals
- Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
- Acurx Pharmaceuticals files $50M mixed shelf offering
- Seeking Alpha’s Quant Rating on Acurx Pharmaceuticals
- Historical earnings data for Acurx Pharmaceuticals
- Financial information for Acurx Pharmaceuticals